2cureX completes SEK 7.51M directed issue
The issue is fully subscribed with demand far exceeding allocation. It signals investor confidence in clinical utility and execution ahead of precision oncology advancements.
See the latest news and media coverage for 2cureX. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of 3D tumoroid drug sensitivity tests
2curex.comLast updated
In short: 2cureX advanced its precision oncology platform via strategic partnerships, launched its first patient test, and secured new funding.
The issue is fully subscribed with demand far exceeding allocation. It signals investor confidence in clinical utility and execution ahead of precision oncology advancements.
The report shows a reduced loss of -1,951 KSEK, cash at 5,098 KSEK, and highlights strategy execution, partnerships, and AI integration. CEO outlines priorities including expansion and approvals.
CEO Nathaniel Hutley presents updates post-AGM, Operation Twin Code progress, AI integration, and global scaling plans. A moderated Q&A follows.
They signed a Letter of Intent to align organoid-based drug response testing platforms under Operation Twin Code. Executives express optimism about building an end-to-end precision oncology platform.
Nasdaq decides to remove 2curex from the market against the company's wishes, making it more difficult for owners to sell their shares.
At close: 5:29:40 pm GMT+2...
As of 11:19:01 CEST. Market open.
The interim report is available as an attached document as well as on the company’s website (https://www.2curex.se). A short summary of the report follows below.CEO...
Track 2cureX and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to 2cureX and other trending companies.